FORMULIERUNGEN AUS BENDAMUSTIN

European patent · EP2827862 · In force

Register entry

Publication number
EP2827862
Application number
EP13764989
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 15, 2013
Published
Jan 28, 2015
Granted
Dec 27, 2023
Protection ends at the latest
Mar 14, 2033
Next annual fee due
Mar 31, 2027
IPC classes
A61K 31/4184 (2006.01)
A61K 47/10 (2017.01)
A61K 47/20 (2006.01)
A61K 9/00 (2006.01)
Priority
US 201261613173 P 20.03.2012
US 201261669889 P 10.07.2012
PCT application
PCT/US2013/032289 15.03.2013
PCT publication
WO2013/142358 26.09.2013
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 1, 2026

    Change

    Published in Swissreg on 01.04.2026

  2. Apr 1, 2025

    Change

    Published in Swissreg on 01.04.2025

  3. Nov 6, 2024

    Change

    Published in Swissreg on 06.11.2024

  4. Apr 2, 2024

    Change

    Published in Swissreg on 02.04.2024

  5. Dec 28, 2023

    Agent entered

    Representative
    E. Blum & Co. AG, Hofwiesenstrasse 349, 8050 Zürich

    Published in Swissreg on 28.12.2023

  6. Dec 27, 2023

    Granted

    Published in Swissreg on 27.12.2023

Parties

Holder

Eagle Pharmaceuticals, Inc.

50 Tice Boulevard Suite 315, Woodcliff Lake, NJ 07677, US

Agent

E. Blum & Co. AG

Hofwiesenstrasse 349, 8050 Zürich

Inventor

SUNDARAM, Srikanth

Somerset, New Jersey 08873, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.